S-1: Ontrak, Inc. Files S-1 for Public Offering Amidst Going Concern Doubts and Significant Dilution Risks

Sentiment:

Registration Statement for Public Offering 16 June 2025 9:36 PM

Ontrak, Inc. has filed an S-1 registration statement for a public offering of common stock and warrants, seeking to raise approximately $6.0 million to address its substantial financial challenges, including significant losses and a going concern warning from its auditor.

Delay expectedOne of the largest active prospects paused its review of Ontrak's proposal due to concerns about the company's financial stability and its ability to deliver as a Medicaid provider in that state. This has delayed the expected timeline to move to the final contracting phase with this prospect.

Capital raiseThe company is undertaking a 'reasonable best efforts' public offering of up to 4,666,666 shares of common stock, up to 4,666,666 pre-funded warrants, and up to 18,666,664 warrants.The offering aims to raise approximately $6.0 million in net proceeds (assuming $7.0 million gross proceeds).The company explicitly states it will need to raise additional capital beyond this offering to fund its operations through the 12-month period following the prospectus date.Acuitas, a major debt holder, has committed to purchase up to an additional $5.0 million in Demand Notes and up to $5.0 million in Non-Convertible Demand Notes under the May 2025 Agreement, subject to certain conditions, including the company's inability to effect a registered equity offering on acceptable terms.

Worse than expectedThe company has incurred significant losses since inception and continues to experience net losses and negative cash flow from operations.Its independent auditor has expressed substantial doubt about the company's ability to continue as a going concern.The company had negative working capital of $3.1 million and only $4.1 million in cash as of March 31, 2025, with a high average monthly cash burn rate of $0.9 million.A significant customer, representing 59% of 2024 revenue, terminated its contract.The company explicitly states it will need to raise additional capital beyond this offering to fund operations for the next 12 months.One of its largest new prospects has paused its review due to concerns about Ontrak's financial stability.

Summary

Ontrak, Inc. is seeking to raise up to $7.0 million in gross proceeds through a 'reasonable best efforts' public offering of up to 4,666,666 shares of common stock, up to 4,666,666 pre-funded warrants, and up to 18,666,664 warrants.
The offering assumes a combined public offering price of $1.50 per share and four warrants, with estimated net proceeds of approximately $6.0 million after deducting fees and expenses.
The company has incurred significant losses since its inception in 2003, reporting negative working capital of $3.1 million and total cash of $4.1 million as of March 31, 2025.
Its average monthly cash burn rate from operations was $0.9 million for the three months ended March 31, 2025.
The company's independent auditor included an explanatory paragraph about substantial doubt concerning Ontrak's ability to continue as a going concern in their report for the year ended December 31, 2024.
Ontrak will need to raise additional capital beyond this offering to fund operations through the 12-month period following the prospectus date.
A significant health plan customer, representing 59% of 2024 revenue ($6.5 million), notified Ontrak in October 2024 of its intent not to continue services after December 2024.
The company is subject to a Nasdaq discretionary panel monitor until October 7, 2025, increasing the risk of delisting if it fails to maintain compliance with any listing requirement.
Warrants offered in this offering, as well as previously issued warrants, contain price-based anti-dilution provisions that could lead to substantial future dilution for stockholders.

Sentiment

Score: 2

Explanation: The company is in a precarious financial position, evidenced by substantial doubt about its ability to continue as a going concern, significant accumulated losses, negative working capital, and a high cash burn rate. The loss of a major customer and the explicit need for further capital beyond this offering underscore severe operational and financial challenges. While attempting to raise capital, the offering terms involve substantial dilution, and the company faces significant Nasdaq delisting risks and ongoing litigation.

Positives

The company is actively attempting to raise capital through a public offering to fund its operations.
Ontrak has five active prospects in later stages of the sales process, with a combined estimated member outreach pool of up to 20,000 lives for Wholehealth+ and 40,000 for Engage.
There are 20 additional active prospects in varying phases of the sales process, representing approximately 15 million plan lives.
Newest health plan customers have indicated an interest in expanding Ontrak's solutions to additional populations once clinical and financial outcomes are achieved.
The company regained compliance with Nasdaq's minimum bid price rule as of October 7, 2024.

Negatives

There is substantial doubt about the company's ability to continue as a going concern, as explicitly stated by its independent auditor.
Ontrak has incurred significant losses since its inception in 2003 and continues to experience net losses and negative cash flow from operating activities.
As of March 31, 2025, the company had negative working capital of $3.1 million and only $4.1 million in total cash.
The average monthly cash burn rate from operations was $0.9 million for the three months ended March 31, 2025.
The company lost a significant health plan customer in October 2024, which accounted for 59% ($6.5 million) of its revenue for the year ended December 31, 2024.
Ontrak's business currently depends upon a few significant customers, and it has lost four significant customers since 2021.
One of the largest new prospects has paused its review of Ontrak's proposal due to concerns about the company's financial stability and its ability to deliver as a Medicaid provider, delaying the sales timeline.
Approximately $15.8 million, including accrued paid-in-kind interest, was outstanding under the Keep Well Agreement as of May 31, 2025, with a significant portion potentially payable after September 1, 2026.
There is a risk that the company may not have sufficient funds to repay amounts due under the Keep Well Agreement if demanded by Acuitas.
New investors in this offering will experience immediate and substantial dilution of $0.94 per share in the pro forma net tangible book value.
Both existing and new warrants contain aggressive price-based anti-dilution provisions that could lead to substantial future dilution, potentially increasing the total number of shares issuable from new warrants to 93,333,320 under certain conditions.
There is no established public trading market for the pre-funded warrants or warrants, limiting their liquidity.
The warrants offered in this offering will not be exercisable unless and until stockholder approval is obtained, which is not assured, rendering them potentially valueless.
The offering is being made on a 'reasonable best efforts' basis with no minimum amount of securities required to be sold, meaning the company may not raise the amount of capital it believes is required for its business plans.

Risks

The company needs additional capital to continue operations and execute its business strategy, and there is no guarantee that adequate additional capital will be raised on a timely basis, on favorable terms, or at all.
There is substantial doubt about the company's ability to continue as a going concern.
The company has incurred significant losses since inception and may be unable to obtain additional funds before achieving positive cash flows.
A default under the Keep Well Agreement or any related promissory notes would have a material adverse effect on the company's financial condition, operating results, and business, potentially leading to insolvency or bankruptcy.
The company's programs and solutions may not be as effective as believed and may not achieve broad market acceptance, which could lead to declines in the market prices of its securities.
The loss of one or more significant customers would have a material adverse effect on the company's financial condition, operating results, and business.
The company depends upon its senior management and key consultants, and their loss or unavailability could put it at a competitive disadvantage.
The company needs to attract and retain highly skilled personnel and may be unable to effectively manage growth with its limited resources.
Customers may not achieve the savings expected to be created by the company's programs and solutions, which could adversely impact the business.
Market acceptance of the company's programs and solutions depends in large part on the willingness of third-party payors to cover them, which is beyond the company's control.
The company may be unable to protect its intellectual property rights and may be liable for infringing the intellectual property rights of others.
Ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on the company's business and results of operations.
The company must comply with significant government regulations, including with respect to licensure and privacy matters.
The Series A Preferred Stock has no fixed maturity date, ranks junior to currently outstanding indebtedness, is entitled to dividends only to the extent permitted by Delaware corporate law, and has limited voting rights.
Acuitas Group Holdings, LLC, as the largest stockholder, controls approximately 46% of outstanding common stock and beneficially owns approximately 97%, giving it substantial influence over corporate matters, including director elections and significant transactions.
The company is subject to ongoing litigation and may be subject to future litigation, any of which could result in substantial liabilities.
There is no assurance that the company's common stock will continue to be listed on Nasdaq or that it will be able to comply with its continued listing requirements, which could limit investors' ability to transact in its securities and subject it to additional trading restrictions.
The price of the company's common stock and preferred stock may be volatile and adversely impacted by future events.
The company's certificate of incorporation, bylaws, and Delaware law have anti-takeover provisions that could discourage, delay, or prevent a change in control, which may cause its stock price to decline.
New investors will experience immediate dilution in the net tangible book value per share of common stock purchased in the offering.
Purchasers may experience future dilution as a result of future equity offerings or other equity issuances.
There is no public market for the warrants or pre-funded warrants being offered, limiting their liquidity.
The warrants will not be exercisable unless and until stockholder approval is obtained, and if not obtained, the warrants will have no value.
The warrants offered in this offering contain price protection in the form of anti-dilution provisions that could harm trading in the common stock and make it difficult to obtain additional financing.
A substantial number of shares of common stock may be sold in the market following this offering, which may depress the market price.
Purchasers who purchase securities pursuant to a securities purchase agreement may have rights not available to other purchasers.
Management has broad discretion in the use of the net proceeds from this offering and may not use them effectively, and Acuitas may require proceeds to pay down debt.
The 'best efforts' nature of the offering means the company may not raise the amount of capital required for its business plans.

Future Outlook

The company anticipates needing to raise additional capital beyond this offering to fund its operations for the next 12 months. It is optimistic about securing new contracts with five key prospects by the end of 2025 and expanding solutions with existing customers, but acknowledges that one large prospect has paused its review due to financial stability concerns.

Management Comments

"We are confident in the proposals we delivered to them [five active prospects], and we are optimistic we can move towards final decisions with them before the end of 2025."
"Our newest health plan customers have indicated an interest in expanding our solutions to additional populations, once clinical and financial outcomes are achieved."

Industry Context

Ontrak, Inc. operates as a value-based behavioral healthcare company in the United States, contracting with national and regional health plans. Its technology-enabled platform uses analytics and predictive modeling to identify connections between behavioral health issues and chronic physical conditions, aiming to improve clinical outcomes and reduce healthcare costs. The company's focus on engaging individuals who might not otherwise seek behavioral healthcare and delivering validated cost savings positions it within the evolving landscape of integrated healthcare solutions. The recent loss of a major customer highlights the competitive and potentially concentrated nature of the health plan market, where contract renewals and new client acquisitions are critical for growth and financial stability.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Stock Split	Effected a 1-for-15 reverse stock split of its common stock, effective September 23, 2024.	2024-09-23	Reduced the number of outstanding shares and proportionally increased the per-share price, but also led to adjustments in warrant exercise prices and shares issuable, contributing to potential dilution.
Voting Rights	Holders of Series A Cumulative Perpetual Preferred Stock have had the right to elect two directors to the board of directors since August 2023.	2023-08	Grants a specific class of stockholders influence over board composition, although no directors have been elected by them as of the prospectus date.
Ownership Concentration	Acuitas Group Holdings, LLC, controlled by former CEO Terren S. Peizer, owns approximately 46% of outstanding common stock and beneficially owns approximately 97%, giving it substantial influence over director elections and other stockholder matters.	2025-05-31	Concentrated ownership allows a single entity significant control over corporate decisions, potentially aligning with its own interests rather than those of other stockholders, and could deter unsolicited takeovers.
Anti-Takeover Provisions	The company's certificate of incorporation, bylaws, and Delaware law contain anti-takeover provisions.	N/A	These provisions could discourage, delay, or prevent a change in control, which may cause the stock price to decline by limiting potential acquisition premiums.

Legal Proceedings

The company is involved in various securities class actions and purported stockholder derivative complaints.
It has incurred legal costs related to an investigation by the SEC and Department of Justice of its former chief executive officer and chairman of the board of directors, Terren S. Peizer.
In June 2024, a federal jury convicted Terren S. Peizer of one count of securities fraud and two counts of insider trading.
On April 29, 2025, the Court found that Mr. Peizer's insider trading had resulted in avoided losses of $12,711,324 and ordered him to forfeit that amount.
Mr. Peizer is set to be sentenced on June 23, 2025.
Neither the company nor any other current or former director or employee has been charged by the DOJ or sued by the SEC in connection with these matters.

Related Party Transactions

The company has a Master Note Purchase Agreement (Keep Well Agreement) with Acuitas Capital LLC (Acuitas), an entity indirectly wholly owned and controlled by Terren S. Peizer, the company's former chief executive officer and chairman of the board of directors.
As of May 31, 2025, approximately $15.8 million, including accrued paid-in-kind interest, was outstanding under the Keep Well Agreement.
Acuitas has provided waivers for non-compliance with recurring revenue and liquidity covenants through June 30, 2025, and for the unqualified going concern opinion in the company's consolidated financial statements for the year ended December 31, 2024.
Under the May 2025 Agreement, Acuitas committed to purchase up to an additional $5.0 million in principal amount of Demand Notes and up to $5.0 million in principal amount of senior secured non-convertible promissory notes (Non-Convertible Demand Notes), subject to certain conditions.
Warrants issued to Acuitas under the Keep Well Agreement, as well as other warrants, contain price-based anti-dilution provisions that have led to significant increases in the number of shares issuable to Acuitas.

Stakeholder Impact

**Shareholders**: Face significant immediate and future dilution from the current offering and the aggressive anti-dilution provisions of existing and new warrants. There is a high risk of losing all or part of their investment due to the company's going concern doubts and potential bankruptcy. The risk of Nasdaq delisting could further reduce liquidity and trading activity for their shares.
**Employees**: The company's severe financial instability and the going concern warning raise concerns about job security and the long-term viability of their employment.
**Customers (Health Plans)**: Existing and prospective customers may have concerns about the company's financial stability and its ability to reliably deliver its programs, as evidenced by one large prospect pausing its review. This could hinder new contract acquisitions and expansion opportunities.
**Creditors (especially Acuitas)**: Acuitas, as a secured creditor with a first priority lien on the company's assets, has significant leverage. In the event of default, Acuitas's claims would take precedence, potentially leaving other creditors with little to no recovery.
**Suppliers**: May face increased risk of delayed or non-payment for services or goods provided if the company's financial condition continues to deteriorate.

Next Steps

Obtain stockholder approval for the exercisability of the warrants offered in this public offering.
Call and hold a special meeting of stockholders (or obtain written consent) within 60 days of warrant issuance to seek stockholder approval.
Continue efforts to secure new contracts with five active prospects and 20 additional prospects.
Seek to expand solutions with newest health plan customers after clinical and financial outcomes are achieved.
Potentially borrow additional funds under the Keep Well Agreement with Acuitas.
File quarterly report on Form 10-Q for the quarter ended June 30, 2025.
Address potential Nasdaq delisting if stockholders' equity falls below $2.5 million at June 30, 2025.
Terren S. Peizer's sentencing is scheduled for June 23, 2025.

Key Dates

Date	Description
2003-09-29	Ontrak, Inc. incorporated in the State of Delaware.
2021	Since this year, the company has lost four significant customers.
2022-04	Company and Acuitas Capital LLC entered into the Master Note Purchase Agreement (Keep Well Agreement).
2022-07	Issued a senior secured note in a principal amount of $5,000,000.
2022-08	Issued 8,219 shares of common stock and a warrant.
2022-09	Issued a senior secured note in the principal amount of $6,000,000 and a warrant.
2022-09	Company was not in compliance with Nasdaq's minimum bid price rule until August 2023.
2023-01	Issued a senior secured note in the principal amount of $4,000,000 and a warrant.
2023-02	Issued 22,646 shares of common stock, exchanged warrants, and issued senior secured convertible notes in the aggregate principal amount of $15.0 million.
2023-03-01	DOJ announced charges and SEC filed a civil complaint against Mr. Peizer.
2023-03	Issued a convertible note in the principal amount of $4,000,000 and a warrant.
2023-08	Holders of Series A Preferred Stock gained the right to elect two directors to the board of directors.
2023-08	Company was not in compliance with Nasdaq's stockholders' equity rule until November 2023.
2023-10	Company was not in compliance with Nasdaq's minimum bid price rule until October 7, 2024.
2023-11	Issued a pre-funded warrant to purchase 1,299,575 shares of common stock and 1,203,653 shares of common stock in connection with the conversion of $16.2 million of convertible notes, and a warrant to purchase up to 7,812,169 shares of common stock.
2023-12	Issued 601,827 additional shares of common stock and adjusted the exercise price and number of shares subject to the Conversion Warrant.
2024-01	Issued 83 shares of common stock in connection with the acquisition of LifeDojo Inc.
2024-03	Entered into the Sixth Amendment to the Master Note Purchase Agreement; exercise price of certain warrants reduced from $11.99 to $4.8557, and aggregate shares increased from 3.8 million to 9.5 million.
2024-04	Issued a convertible note in the principal amount of $1,500,000 and a warrant.
2024-05	Issued a convertible note in the principal amount of $1,500,000 and a warrant.
2024-06	A federal jury convicted Terren S. Peizer of one count of securities fraud and two counts of insider trading; issued a convertible note in the principal amount of $1,500,000 and a warrant.
2024-08	Entered into an agreement with Acuitas pursuant to which Acuitas agreed to purchase an aggregate of $5.0 million of Committed Demand Notes; issued a convertible note in the principal amount of $1,500,000 and a warrant.
2024-09-23	A 1-for-15 reverse stock split of common stock became effective at 12:01 a.m. Eastern Time.
2024-09	Issued a convertible note in the principal amount of $1,000,000 and a warrant.
2024-10-07	Received a letter from Nasdaq confirming regained compliance with the Minimum Bid Price Rule and initiation of a one-year discretionary panel monitor.
2024-10	Notified by a health plan customer of its intent not to continue using services after December 2024; exercise price of certain warrants reduced to $2.25 and $2.08, and aggregate shares increased from approximately 3.3 million to 7.4 million due to the reverse stock split.
2024-10	Issued a convertible note in the principal amount of $1,000,000 and a warrant.
2024-12-31	Financial statements for the year ended were prepared under the assumption of continuing as a going concern; lost customer's services ceased after this date.
2025-03	Issued a convertible note in the principal amount of $1,500,000 and a warrant.
2025-03-31	Total cash was $4.1 million, and negative working capital was $3.1 million; 4,217,848 shares of common stock outstanding.
2025-04-08	Acuitas waived non-compliance with recurring revenue and liquidity covenants through June 30, 2025, and the unqualified going concern opinion for 2024 financial statements.
2025-04-14	Auditor's report dated; Annual Report on Form 10-K filed.
2025-04-29	Court found Mr. Peizer's insider trading resulted in avoided losses of $12,711,324 and ordered forfeiture of that amount.
2025-05-09	Issued a Demand Note to Acuitas in the original principal amount of $0.5 million and a Demand Warrant to purchase approximately 609,756 shares of common stock.
2025-05-19	Entered into the May 2025 Agreement with Acuitas relating to the Keep Well Agreement.
2025-05	Lowest VWAP of common stock was $1.553; exercise price of certain warrants reduced to $1.553, and aggregate shares increased from 42,304,917 to 56,134,451.
2025-05	Issued a convertible note in the principal amount of $0.5 million and a warrant.
2025-05	Issued a convertible note in the principal amount of $1.3 million and a warrant.
2025-05-31	Approximately $15.8 million, including accrued paid-in-kind interest, was outstanding under the Keep Well Agreement; Acuitas Group Holdings, LLC owned approximately 46% of outstanding common stock and beneficially owned approximately 97%.
2025-06-11	Closing price of common stock on Nasdaq was $1.50 per share.
2025-06-15	Company had five active prospects in later stages of the sales process and 20 additional active prospects.
2025-06-16	Registration Statement on Form S-1 filed with the SEC.
2025-06-23	Terren S. Peizer is set to be sentenced.
2025-10-07	End date of the one-year Nasdaq discretionary panel monitor period.
2025-12-31	Expected timeline for final decisions with five key prospects before the end of this year.
2026-05-14	Maturity date for the balance of the Keep Well Agreement debt.
2026-09-01	Earliest date for payment demand on $13.0 million of Demand Notes under the Keep Well Agreement.
2027-06-20	Date related to certain warrant exercise price adjustments.

Recommendation

strong sell

Keywords

Ontrak Inc., OTRK, SEC filing, S-1, public offering, common stock, warrants, pre-funded warrants, going concern, dilution, capital raise, financial health, Nasdaq listing, debt financing, Keep Well Agreement, Acuitas Capital, behavioral healthcare, health plans, risk factors, corporate governance, securities fraud, insider trading

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.